The Chronic Obstructive Pulmonary Disease Market is estimated to be USD 25.06 billion in 2025, projected to reach USD 36.68 billion by 2033, with a CAGR of 4.89%. The U.S. market size is USD 6.93 billion in 2025, expected to grow at a CAGR of 4.66%. Major companies include AstraZeneca, Novartis, and Pfizer. Bronchodilators dominate the market at 48.10%, with corticosteroids growing at 5.04%. Chronic bronchitis leads at 60.80%, while emphysema grows at 3.60%. Treatment is at 65.10%, with diagnostics growing at 3.90%. Hospital pharmacies lead at 50.36%, while online pharmacies grow at 5.50%. North America dominates the market, while Asia Pacific is expected to have the fastest-growing CAGR of 5.99%. Recent developments include Novartis partnering with Viz.ai and Abbott launching a new digital health platform for COPD management. The report also includes environmental impact metrics, lifestyle impact data, innovation indicators, and competitive landscape analysis. SNS Insider offers a comprehensive report on the Chronic Obstructive Pulmonary Disease (COPD) market, providing in-depth analysis and insights. With a focus on delivering current and accurate market data, the report aims to equip clients with the knowledge needed to make informed decisions in a rapidly changing environment. Various research techniques are employed to gather consumer insights and opinions globally.

For more information or to request customization, contact SNS Insider at [email protected]. As a leading market research and consulting agency, SNS Insider is dedicated to providing clients with the tools and information necessary to navigate evolving market conditions. Through surveys, video talks, and focus groups, the company ensures the delivery of reliable data for confident decision-making.

Read more at GlobeNewswire: Chronic Obstructive Pulmonary Disease Market Size to Reach